|Table of Contents|

Efficacy and safety of sindilizumab combined with chemotherapy in neoadjuvant treatment of locally progressive gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 04
Page:
628-635
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of sindilizumab combined with chemotherapy in neoadjuvant treatment of locally progressive gastric cancer
Author(s):
DENG Zhongquan1; CHEN Dezhen1; ZHU Haiqiang1; WU Jiaming2
1.Zhejiang University of Traditional Chinese Medicine,Zhejiang Hangzhou 310053,China;2.Jiaxing First Hospital(Affiliated Hospital of Jiaxing University),Zhejiang Jiaxing 314000,China.
Keywords:
locally progressive gastric cancer; sindilizumab; neoadjuvant therapy
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2025.04.012
Abstract:
Objective:To examine the recent efficacy and safety of capecitabine+oxaliplatin(XELOX) combined with PD-1 inhibitor sindilizumab in locally progressive gastric neoadjuvant therapy.Methods:The clinicopathological data of 74 cases of locally progressive gastric cancer treated with neoadjuvant therapy in the Department of Gastrointestinal Surgery of Jiaxing No.1 Hospital from September 2020 to September 2023 were collected.Based on the different neoadjuvant treatment protocols,the patients receiving XELOX protocol were set up as the control group(n=38),and the combination of the PD-1 inhibitor sindilizumab with XELOX was set as the observation group(n=36).In the observation group(n=36),the pathological complete remission(PCR) rate,major pathological remission(MPR) rate,objective remission rate(ORR),and the occurrence of adverse reactions associated with neoadjuvant PD-1 immunotherapy in combination with chemotherapy and neoadjuvant chemotherapy alone were investigated.Results:The pathological complete remission rate of the observation group was higher than that of the control group［27.8%(10/36) vs 7.9%(3/38)］,as was the major pathological remission rate［47.2%(17/36) vs 23.7%(9/38)］.The ORR of the observation group was higher than that of the control group after three cycles of neoadjuvant therapy in both groups［52.8%(19/36) vs 26.3%(10/38)］.Furthermore,the differences in PCR rate,MPR rate,and ORR between the two groups were statistically significant.The Chi-squared test yielded statistically significant results for the following variables:MPR rate(χ2=4.49,P=0.034),ORR(χ2=5.43,P=0.020),and PCR rate(χ2=5.05,P=0.025) between the two groups.The most common adverse reactions in both groups were hematological toxicity,gastrointestinal reactions(diarrhea,nausea,vomiting),liver and renal function impairment,skin damage,pneumonia,hypothyroidism,and so forth.Of these,less than 15% were grade 3 to 4 adverse reactions.Conclusion:For preoperative neoadjuvant treatment of locally progressive gastric cancer.The combination of sindilizumab on top of the XELOX chemotherapy regimen has a favorable near-term efficacy and safety profile.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］ BANG YJ,RUIZ EY,VAN CUTSEM E,et al.Phase III,randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer:primary analysis of JAVELIN Gastric 300［J］.Annals of Oncology,2018,29(10):2052-2060.
［3］ LAMARCA A,MOLINA R,MARTINEZ-AMORES B,et al.Routine use of perioperative chemotherapy for resectable gastroesophageal cancer［J］.Annals of Oncology,2013,24:iv59.
［4］ NOH SH,PARK SR,YANG HK,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial［J］.The Lancet Oncology,2014,15(12):1389-1396.
［5］ ZHANG X,LI Z,LIANG H,et al.LBA78 overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy:An updated analysis of RESOLVE trial［J］.Annals of Oncology,2023,34:S1318-S1319.
［6］ SMYTH EC,WOTHERSPOON A,PECKITT C,et al.Mismatch repair deficiency,microsatellite instability,and survival:An exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy(MAGIC) trial［J］.JAMA Oncology,2017,3(9):1197.
［7］ AJANI JA,D' AMICO TA,BENTREM DJ,et al.Gastric cancer,version 2.2022,NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network,2022,20(2):167-192.
［8］ YCHOU M,BOIGE V,PIGNON JP,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:An FNCLCC and FFCD multicenter phase III trial［J］.Journal of Clinical Oncology,2011,29(13):1715-1721.
［9］ SCHUHMACHER C,GRETSCHEL S,LORDICK F,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European organisation for research and treatment of cancer randomized trial 40954［J］.Journal of Clinical Oncology,2010,28(35):5210-5218.
［10］ JANJIGIAN YY,SHITARA K,MOEHLER M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial［J］.The Lancet,2021,398(10294):27-40.
［11］ BOKU N,RYU MH,KATO K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer:interim results of a randomized,phase II trial(ATTRACTION-4)［J］.Annals of Oncology,2019,30(2):250-258.
［12］ CHAO J,FUCHS CS,SHITARA K,et al.Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059,KEYNOTE-061,and KEYNOTE-062 clinical trials［J］.JAMA Oncology,2021,7(6):895.
［13］ XU J,JIANG H,PAN Y,et al.Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer:The ORIENT-16 randomized clinical trial［J］.JAMA,2023,330(21):2064.
［14］ Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2021(6th edition)［J］.Gastric Cancer,2023,26(1):1-25.
［15］ EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)［J］.European Journal of Cancer,2009,45(2):228-247.
［16］ NICHOLLS RJ,ZINICOLA R,HABOUBI N.Extramural spread of rectal cancer and the AJCC cancer staging manual 8th edition,2017［J］.Annals of Oncology,2019,30(8):1394-1395.
［17］ GILBERT A,PICCININ C,VELIKOVA G,et al.Linking the European organisation for research and treatment of cancer item library to the common terminology criteria for adverse events［J］.Journal of Clinical Oncology,2022,40(32):3770-3780.
［18］ DINDO D,DEMARTINES N,CLAVIEN PA.Classification of surgical complications:A new proposal with evaluation in a cohort of 6336 patients and results of a survey［J］.Annals of Surgery,2004,240(2):205-213.
［19］ QUESADA S,SAMALIN E,THEZENAS S,et al.Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma［J］.Anticancer Research,2022,42(1):185-193.
［20］ AL-BATRAN SE,HOFHEINZ RD,PAULIGK C,et al.Histopathological regression after neoadjuvant docetaxel,oxaliplatin,fluorouracil,and leucovorin versus epirubicin,cisplatin,and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4-AIO):results from the phase 2 part of a multicentre,open-label,randomised phase 2/3 trial［J］.The Lancet Oncology,2016,17(12):1697-1708.
［21］ WAGNER AD,GROTHE W,HAERTING J,et al.Chemotherapy in advanced gastric cancer:A systematic review and Meta-analysis based on aggregate data［J］.Journal of Clinical Oncology,2006,24(18):2903-2909.
［22］ SHITARA K,VAN CUTSEM E,BANG YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:The KEYNOTE-062 phase 3 randomized clinical trial［J］.JAMA Oncology,2020,6(10):1571.
［23］ WANG Y,XU H,HU C,et al.Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma:a retrospective cohort study［J］.Journal of Gastrointestinal Oncology,2022,13(3):1046-1057.
［24］ XU C,XIE X,KANG N,et al.Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients:a multicentered,prospective,cohort study［J］.Journal of Cancer Research and Clinical Oncology,2023,149(7):4091-4099.
［25］ JIANG H,YU X,LI N,et al.Efficacy and safety of neoadjuvant sintilimab,oxaliplatin and capecitabine in patients with locally advanced,resectable gastric or gastroesophageal junction adenocarcinoma:early results of a phase 2 study［J］.Journal for ImmunoTherapy of Cancer,2022,10(3):e003635.
［26］ LIN JL,LIN JX,LIN JP,et al.Safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion［J］.Frontiers in Immunology,2022,12:783243.
［27］ YIN Y,LIN Y,YANG M,et al.Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil(S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer:Early results of a phase 2,single-arm trial［J］.Frontiers in Oncology,2022,12:959295.
［28］ YANG F,WANG JF,WANG Y,et al.Comparative analysis of predictive biomarkers for PD-1/PD-L1 inhibitors in cancers:Developments and challenges［J］.Cancers,2021,14(1):109.

Memo

Memo:
浙江省医药卫生科技计划项目(编号：2024KY431)
Last Update: 1900-01-01